PK and Safety Study of BIIB074 in Healthy Japanese and Caucasian Participants
A Phase 1 Pharmacokinetics and Safety Study of BIIB074 in Healthy Japanese and Caucasian Subjects
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
-
Leeds, Det Forenede Kongerige, LS2 9LH
- Research Site
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Key Inclusion Criteria:
- Japanese or Caucasian.
- Japanese participants must have been born in Japan, and their biological parents and grandparents must all have been of Japanese origin.
- Must have a body mass index between 18 and 30 kg/m2, inclusive.
Key Exclusion Criteria:
- Previous exposure to BIIB074, with the exception that Japanese participants who complete Part 1.
- Use of any oral, injected, or implanted hormonal method of contraception that contains ethinyl estradiol within 28 days of Day -1 and an unwillingness to refrain from product use during study participation.
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Tredobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Part 1
48 participants: Cohorts 1,2 and 3 (Single Ascending Dose of BIIB074 or placebo) in a 6:2 ratio
|
Indgives som specificeret i behandlingsarmen
Andre navne:
Matchet placebo
|
|
Eksperimentel: Part 2
16 participants: Multiple Ascending Dosing of BIIB074 or placebo in a 6:2 ratio; 3 times daily [TID] in cohort 4 for 6 days and one time (QD) for 1 day and 2 times daily [BID] in cohort 5 for 6 days and QD for 1 day
|
Indgives som specificeret i behandlingsarmen
Andre navne:
Matchet placebo
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Part 1: PK of BIIB074 single oral dose as assessed by maximum observed concentration (Cmax )
Tidsramme: 15 minutes prior to dosing up to 96 hours post dose
|
15 minutes prior to dosing up to 96 hours post dose
|
|
Part 1: PK of BIIB074 single oral dose as assessed by time to reach Cmax (tmax)
Tidsramme: 15 minutes prior to dosing up to 96 hours post dose
|
15 minutes prior to dosing up to 96 hours post dose
|
|
Part 1: PK of BIIB074 single oral dose as assessed by area under the concentration time curve from time 0 extrapolated to infinity (AUCinf)
Tidsramme: 15 minutes prior to dosing up to 96 hours post dose
|
15 minutes prior to dosing up to 96 hours post dose
|
|
Part 1: PK of BIIB074 single oral dose as assessed by area under the concentration time curve from time 0 to time of the last measurable drug concentration (AUC0-t)
Tidsramme: 15 minutes prior to dosing up to 96 hours post dose
|
15 minutes prior to dosing up to 96 hours post dose
|
|
Part 1: PK of BIIB074 single oral dose as assessed by terminal elimination half-life (t1/2)
Tidsramme: 15 minutes prior to dosing up to 96 hours post dose
|
15 minutes prior to dosing up to 96 hours post dose
|
|
Part 1: PK of BIIB074 single oral dose as assessed by apparent volume of distribution (Vd/F)
Tidsramme: 15 minutes prior to dosing up to 96 hours post dose
|
15 minutes prior to dosing up to 96 hours post dose
|
|
Part 1: PK of BIIB074 single oral dose as assessed by apparent total body clearance (CL/F)
Tidsramme: 15 minutes prior to dosing up to 96 hours post dose
|
15 minutes prior to dosing up to 96 hours post dose
|
|
Part 1: PK of BIIB074 single oral dose as assessed by metabolite to parent ratio in AUC (MRAUC)
Tidsramme: 15 minutes prior to dosing up to 96 hours post dose
|
15 minutes prior to dosing up to 96 hours post dose
|
|
Part 2: PK of BIIB074 repeated oral dose as assessed by Cmax
Tidsramme: 15 minutes prior to dosing on Day 1 up to 96 hours post dose on Day 7
|
15 minutes prior to dosing on Day 1 up to 96 hours post dose on Day 7
|
|
Part 2: PK of BIIB074 repeated oral dose as assessed by tmax
Tidsramme: 15 minutes prior to dosing on Day 1 up to 96 hours post dose on Day 7
|
15 minutes prior to dosing on Day 1 up to 96 hours post dose on Day 7
|
|
Part 2: PK of BIIB074 repeated oral dose as assessed by area under the concentration time curve within a dosing interval (AUCtau)
Tidsramme: 15 minutes prior to dosing on Day 1 up to 96 hours post dose on Day 7
|
15 minutes prior to dosing on Day 1 up to 96 hours post dose on Day 7
|
|
Part 2: PK of BIIB074 repeated oral dose as assessed by trough concentration after repeated doses (Ctrough)
Tidsramme: 15 minutes prior to dosing on Day 1 up to 96 hours post dose on Day 7
|
15 minutes prior to dosing on Day 1 up to 96 hours post dose on Day 7
|
|
Part 2: PK of BIIB074 repeated oral dose as assessed by t1/2
Tidsramme: 15 minutes prior to dosing on Day 1 up to 96 hours post dose on Day 7
|
15 minutes prior to dosing on Day 1 up to 96 hours post dose on Day 7
|
|
Part 2: PK of BIIB074 repeated oral dose as assessed by apparent volume of distribution at steady state (Vss/F)
Tidsramme: 15 minutes prior to dosing on Day 1 up to 96 hours post dose on Day 7
|
15 minutes prior to dosing on Day 1 up to 96 hours post dose on Day 7
|
|
Part 2: PK of BIIB074 repeated oral dose as assessed by apparent clearance at steady state (CLss/F)
Tidsramme: 15 minutes prior to dosing on Day 1 up to 96 hours post dose on Day 7
|
15 minutes prior to dosing on Day 1 up to 96 hours post dose on Day 7
|
|
Part 2: PK of BIIB074 repeated oral dose as assessed by accumulation ratio (Rac)
Tidsramme: 15 minutes prior to dosing on Day 1 up to 96 hours post dose on Day 7
|
15 minutes prior to dosing on Day 1 up to 96 hours post dose on Day 7
|
|
Part 2: PK of BIIB074 repeated oral dose as assessed by MRAUC
Tidsramme: 15 minutes prior to dosing on Day 1 up to 96 hours post dose on Day 7
|
15 minutes prior to dosing on Day 1 up to 96 hours post dose on Day 7
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Number of participants experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs)
Tidsramme: Up to 2 weeks post Part 2 of the Treatment Period
|
Up to 2 weeks post Part 2 of the Treatment Period
|
|
Number of participants with clinically significant laboratory assessment abnormalities
Tidsramme: Up to 2 weeks post Part 2 of the Treatment Period
|
Up to 2 weeks post Part 2 of the Treatment Period
|
|
Number of participants with clinically significant vital sign abnormalities
Tidsramme: Up to 2 weeks post Part 2 of the Treatment Period
|
Up to 2 weeks post Part 2 of the Treatment Period
|
|
Number of participants with clinically significant 12-lead electrocardiograms (ECGs) abnormalities
Tidsramme: Up to 2 weeks post Part 2 of the Treatment Period
|
Up to 2 weeks post Part 2 of the Treatment Period
|
|
Number of participants with clinically significant physical examinations abnormalities
Tidsramme: Up to 2 weeks post Part 2 of the Treatment Period
|
Up to 2 weeks post Part 2 of the Treatment Period
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- 802HV106
- 2016-000874-39 (EudraCT nummer)
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .